Geron (GERN) Fundamentals 2026 — Revenue Analysis | SniperIQ
Geron (GERN) is a US-listed Healthcare company in Biotechnology with a market capitalization of $905M, trading at
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Geron's market cap?
Geron (GERN) has a market capitalization of approximately $905M, trading at
What is Geron's P/E ratio?
Geron's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 4.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Geron?
Geron runs a net profit margin of -35.5%, a gross margin of 86.6%, and an operating margin of -19.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Geron generate?
Geron reported revenue of
Does Geron pay a dividend?
Geron does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Geron financially healthy?
Geron carries a debt-to-equity ratio of 1.10x and a current ratio of 6.78x, with a market beta of 0.60. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Geron a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Geron (GERN) the key facts are: market cap $905M, revenue
Track Geron's full fundamentals live
Get Geron's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.